Endocrine Gland Neoplasms  >>  Signifor LAR (pasireotide long acting release)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Signifor LAR (pasireotide long acting release) / Recordati
COOPERATE-1, NCT01374451 / 2010-023183-40: Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Terminated
2
160
Japan, US, Canada, Europe, RoW
Everolimus, RAD001, Pasireotide LAR, SOM230 LAR
Novartis Pharmaceuticals
Islet Cell Tumor
02/15
02/15
NCT00958841 / 2008-007348-32: Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Terminated
2
118
US, Canada, Europe, RoW
pasireotide LAR, SOM230
Novartis Pharmaceuticals
Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
06/15
06/15
Passion I, NCT01283542: Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.

Completed
2
20
RoW
Pasireotide LAR
Novartis Pharmaceuticals
Non-functioning Pituitary Adenoma
09/17
09/17

Download Options